Biomarker ID | 512 |
PMID | 20068566 |
Year | 2010 |
Biomarker | ERG expression in TMPRSS2–ERG |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in Fusion (3.07-fold) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include(TMPRSS2):- Androgen receptor regulation of biosynthesis and transcription,Androgen receptor proteolysis and transcription regulation;Pathways Include(ERG):-Genes targeted by miRNAs in adipocytes WP1992,VEGFA-VEGFR2 Signaling Pathway WP3888 |
Experiment | ERG Fusion Vs No Fusion |
Type of Biomarker | Prognostic |
Cohort | Total of 139 patients (GSE18655) were chosen for this study out of which 69 were fusion positive and 70 were fusion negative and 33 experienced biochemical recurrence. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=3.48E-11 |
Method Used | cDNA mediated , annealing, selection, extension and litigation (DASL) |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on Independent Patient Dataset |
Technical Name | TMPRSS2, ERG |